A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)

被引：0
作者：
Nazha, Aziz [1 ]
Seastone, David J. [1 ]
Radivoyevitch, Tomas [1 ]
Gerds, Aaron T. [1 ]
Mukherjee, Sudipto [1 ]
Carraway, Hetty E. [1 ]
Advani, Anjali S. [1 ]
Kalaycio, Matt E. [1 ]
Rupp, Gina [1 ]
Colaluka, Kristin [1 ]
Hobson, Sean [1 ]
Maciejewski, Jaroslaw P. [1 ]
Sekeres, Mikkael A. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
    Mishra, Asmita
    Corrales-Yepez, Maria
    Al Ali, Najla
    Kharfan-Dabaja, Mohamed
    Padron, Eric
    Zhang, Ling
    Epling-Burnette, Pearlie K.
    Pinilla-Ibarz, Javier
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (07) : 566 - 570
  • [42] Has cytogenetic evolution any prognostic relevance in myelodysplastic syndromes (MDS)? A study on 153 patients.
    Bernasconi, Paolo
    Klersy, Catherine
    Boni, Marina
    Cavigliano, Paola Maria
    Calatroni, Silvia
    Giardini, Ilaria
    Rocca, Barbara
    Zappatore, Rita
    Dambruoso, Irene
    Caresana, Marilena
    Lazzarino, Mario
    BLOOD, 2007, 110 (11) : 725A - 726A
  • [43] Expression of CD7 in myelodysplastic syndromes (MDS):: Is this a truly prognostic factor?
    Font, Patricia
    Subira, Dolores
    LEUKEMIA RESEARCH, 2008, 32 (01) : 185 - 186
  • [44] Cytogenetic abnormalities at diagnosis are the most important prognostic factor in the myelodysplastic syndromes (MDS)
    Buckstein, R
    Crump, M
    Imrie, K
    Sutton, D
    Pantalony, D
    Sher, G
    Stewart, AK
    Keating, A
    BLOOD, 1996, 88 (10) : 2317 - 2317
  • [45] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [46] CLINICIAN UTILIZATION OF THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) FOR NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS
    Pease, D.
    Ross, J.
    Poynter, J.
    Nguyen, P.
    Hirsch, B.
    Cioc, A.
    Roesler, M.
    Warlick, E.
    LEUKEMIA RESEARCH, 2015, 39 : S118 - S118
  • [47] Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Lhotska, Halka
    Svobodova, Karla
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Krejcik, Zdenek
    Belickova, Monika
    Siskova, Magda
    Jonasova, Anna
    Neuwirtova, Radana
    Zmolikova, Jana
    Cermak, Jaroslav
    BLOOD, 2014, 124 (21)
  • [48] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [49] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092
  • [50] Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
    Komrokji, Rami S.
    Kulasekararaj, Austin G.
    Al Ali, Najla H.
    Kordasti, Shahram Y.
    Bart-smith, Emily
    Benjamin, Craig
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan
    Mufti, Ghulam J.
    Epling-Burnette, Pearlie K.
    BLOOD, 2013, 122 (21)
12345